The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) (ANZUP trial 0901).
Ian D. Davis
Consultant or Advisory Role - Bayer (U); GlaxoSmithKline (U); Novartis (U); Pfizer (U)
Research Funding - Bayer; GlaxoSmithKline; Novartis; Pfizer
Val Gebski
No relevant relationships to disclose
Mark D. Chatfield
No relevant relationships to disclose
Peter S. Grimison
Research Funding - Novartis
George Kannourakis
Consultant or Advisory Role - Pfizer
Research Funding - Novartis
Amy L Boland
No relevant relationships to disclose
Jennifer Thompson
Other Remuneration - ANZUP Cancer Trials Group
Martin R. Stockler
Research Funding - Bayer; Novartis